Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA) has
designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the
treatment of patients with advanced melanoma. Lambrolizumab is Merck’s
investigational antibody therapy targeting Programmed Death receptor
(PD-1) that is currently being evaluated for the treatment of patients
with advanced melanoma, and other tumor types.
Language:
English
Contact HTML:
MerckMedia:Caroline Lapppetito, 267-305-7639orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Source Type: news